JP2013511522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511522A5 JP2013511522A5 JP2012539887A JP2012539887A JP2013511522A5 JP 2013511522 A5 JP2013511522 A5 JP 2013511522A5 JP 2012539887 A JP2012539887 A JP 2012539887A JP 2012539887 A JP2012539887 A JP 2012539887A JP 2013511522 A5 JP2013511522 A5 JP 2013511522A5
- Authority
- JP
- Japan
- Prior art keywords
- daptomycin
- containing composition
- stable
- long
- term storage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26369509P | 2009-11-23 | 2009-11-23 | |
| US61/263,695 | 2009-11-23 | ||
| US37180210P | 2010-08-09 | 2010-08-09 | |
| US61/371,802 | 2010-08-09 | ||
| PCT/US2010/049322 WO2011062676A1 (en) | 2009-11-23 | 2010-09-17 | Formulations of daptomycin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013511522A JP2013511522A (ja) | 2013-04-04 |
| JP2013511522A5 true JP2013511522A5 (enExample) | 2013-11-07 |
Family
ID=44059911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539887A Pending JP2013511522A (ja) | 2009-11-23 | 2010-09-17 | ダプトマイシン製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110124551A1 (enExample) |
| EP (1) | EP2504020A4 (enExample) |
| JP (1) | JP2013511522A (enExample) |
| CA (1) | CA2774094A1 (enExample) |
| WO (1) | WO2011062676A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2781666C (en) | 2009-11-23 | 2017-02-21 | Cubist Pharmaceuticals, Inc. | Lipopeptide compositions and related methods |
| JP5913367B2 (ja) | 2011-01-05 | 2016-04-27 | ホスピーラ インコーポレイテッド | バンコマイシンの噴霧乾燥 |
| MX2013013760A (es) * | 2011-05-26 | 2014-01-08 | Cubist Pharm Inc | Composiciones de cb-183, 315 y metodos relacionados. |
| PL4066849T3 (pl) * | 2012-09-11 | 2025-06-16 | Hospira Australia Pty Ltd | Preparaty daptomycyny i ich zastosowania |
| WO2014158952A1 (en) | 2013-03-13 | 2014-10-02 | Theravance, Inc. | Hydrochloride salts of an antibiotic compound |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| CN104511011A (zh) * | 2013-09-29 | 2015-04-15 | 山东新时代药业有限公司 | 一种达托霉素无菌粉末及其制备方法 |
| CN104387444B (zh) * | 2014-11-13 | 2017-12-08 | 北大医药重庆大新药业股份有限公司 | 一种达托霉素杂质rs‑2高纯度样品的制备方法 |
| CN106943587B (zh) * | 2016-01-06 | 2021-06-22 | 山东新时代药业有限公司 | 一种注射用达托霉素冻干粉针及其制备工艺 |
| CN105699554B (zh) * | 2016-03-10 | 2017-08-01 | 杭州华东医药集团新药研究院有限公司 | 高纯度达托霉素内酯水解物及其应用 |
| WO2018073269A1 (en) | 2016-10-21 | 2018-04-26 | Xellia Pharmaceuticals Aps | Liquid formulations of daptomycin |
| US11759497B2 (en) | 2017-08-31 | 2023-09-19 | Xellia Pharmaceuticals Aps | Daptomycin formulations |
| WO2020128506A1 (en) | 2018-12-21 | 2020-06-25 | Arecor Limited | Novel composition |
| CA3136500A1 (en) | 2019-05-10 | 2020-11-19 | Xellia Pharmaceuticals Aps | Daptomycin aqueous formulations |
| CN111103373B (zh) * | 2020-01-03 | 2022-04-19 | 丽珠集团福州福兴医药有限公司 | 一种达托霉素的检测方法 |
| EP4110303A1 (en) | 2020-02-28 | 2023-01-04 | Xellia Pharmaceuticals ApS | Daptomycin formulation |
| EP4117625A1 (en) | 2020-03-12 | 2023-01-18 | Baxter International Inc. | Daptomycin formulations containing a combination of sorbitol and mannitol |
| CN114788814B (zh) * | 2021-01-26 | 2023-10-13 | 浙江创新生物有限公司 | 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用 |
| WO2025037189A1 (en) * | 2023-08-11 | 2025-02-20 | Intas Pharmaceuticals Ltd. | Daptomycin formulation |
| WO2025037188A1 (en) * | 2023-08-11 | 2025-02-20 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition of daptomycin. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2011365A1 (en) * | 1989-03-06 | 1990-09-06 | Eugene L. Inman | Diluent formulation for daptomycin |
| US6696412B1 (en) * | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| US7527807B2 (en) * | 2000-06-21 | 2009-05-05 | Cubist Pharmaceuticals, Inc. | Compositions and methods for increasing the oral absorption of antimicrobials |
| US6716962B2 (en) * | 2000-07-17 | 2004-04-06 | Micrologix Biotech Inc. | Extractive purification of lipopeptide antibiotics |
| WO2002059145A1 (en) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
| US20060014674A1 (en) * | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| JP2004525108A (ja) * | 2000-12-18 | 2004-08-19 | キュービスト ファーマスーティカルズ インコーポレイテッド | 精製リポペプチドの調製方法 |
| TWI367759B (en) * | 2003-02-20 | 2012-07-11 | Santarus Inc | A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid |
| US20070202051A1 (en) * | 2006-02-10 | 2007-08-30 | Pari Gmbh | Aerosols for sinunasal drug delivery |
-
2010
- 2010-09-17 US US12/885,009 patent/US20110124551A1/en not_active Abandoned
- 2010-09-17 EP EP10831938.5A patent/EP2504020A4/en not_active Withdrawn
- 2010-09-17 WO PCT/US2010/049322 patent/WO2011062676A1/en not_active Ceased
- 2010-09-17 CA CA2774094A patent/CA2774094A1/en not_active Abandoned
- 2010-09-17 JP JP2012539887A patent/JP2013511522A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011088913A5 (enExample) | ||
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| EP2528602A4 (en) | FORMULAS FROM BENDAMUSTIN | |
| JP2015525762A5 (enExample) | ||
| JP2012092110A5 (enExample) | ||
| JP2017507973A5 (enExample) | ||
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| CY1122516T1 (el) | Ετοιμες προς χρηση διατυπωσεις κετορολακης | |
| JP2018140990A5 (enExample) | ||
| MY166045A (en) | Abeta antibody formulation | |
| JP2013520405A5 (enExample) | ||
| JP2015527402A5 (enExample) | ||
| MX362382B (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
| AR088380A1 (es) | Formulaciones de etanercept estabilizadas con cloruro de sodio | |
| PE20121517A1 (es) | Compuestos lipopeptidos y metodos relacionados | |
| CL2012001841A1 (es) | Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico. | |
| CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| JP2013529072A5 (enExample) | ||
| RU2016150678A (ru) | ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| MX352949B (es) | Composicion farmaceutica. | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| JP2009531457A5 (enExample) | ||
| FI3777833T3 (fi) | Dopa-dekarboksylaasin estäjän koostumuksia | |
| JP2013508315A5 (enExample) | ||
| EA201491513A1 (ru) | Рекомбинантные штаммы escherichia coli |